TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Alaya.bio and a Leading Global Cancer Center Establish a Significant Collaboration to Advance in Situ Car-T Therapy

Friday, January 19, 2024

Alaya.bio, a biotech company specializing in the development of a novel polymeric delivery platform for in situ cell therapies, has announced a collaboration with Dr. Michel Sadelain, a pioneer in CAR-T cell therapies and the Director of the Center for Cell Engineering at the Memorial Sloan Kettering Cancer Center (MSK) in New York City. As part of the collaboration, Dr. Sadelain will become a scientific co-founder of Alaya.bio, and the partnership includes a license agreement and a sponsored research agreement. Over the next two years, Dr. Sadelain's lab will lead efforts to advance Alaya.bio's polymeric delivery platform into clinical applications for a selected hematological malignancy.

Alaya.bio is working on an in situ CAR solution, aiming to address the challenges associated with traditional ex vivo CAR therapies, such as complexity, long manufacturing cycles, and high costs. The company's proprietary polymeric in situ delivery platform utilizes a targeting agent on the polymeric shell to precisely guide nanoparticles to T-cells, ensuring the efficient and safe delivery of therapeutic cargo. This approach is designed to achieve stable expression of the CAR transgene and protect transduced T-cells from exhaustion, critical for long-term clinical benefits.

Dr. Cécile Bauche, co-founder and CSO at Alaya.bio, expresses pride in collaborating with MSK and Dr. Sadelain, emphasizing the significance of the partnership in advancing the in situ CAR-T platform. Dr. Sadelain applauds the ingenuity of Alaya.bio's technology, anticipating its potential to simplify and enhance the development, manufacturing, and administration of CAR-T cell therapies. Renaud Vaillant, co-founder and CEO of Alaya.bio, highlights that the collaboration will expedite the validation of their polymeric delivery platform, with plans to explore additional therapeutic areas and innovative payloads such as mRNA and gene editing technologies.

Renaud Vaillant is set to present details about the collaboration at the MSK Life Sciences Innovation Showcase on January 26, 2024, in New York City.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit